Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy Fleischmann

Showing results (21-30 of 190) with videos related to

Pageof 19
Sort By:
Nature Clinical Practice. Rheumatology|August 1, 2007
Primer: establishing a clinical trial unit--obtaining studies and patientsRoy Fleischmann
Expert Opinion on Biological Therapy|March 17, 2010
The clinical efficacy and safety of certolizumab pegol in rheumatoid arthritisRoy Fleischmann
The Journal of Rheumatology|April 16, 2021
The Results of Well-conducted Negative Clinical Trials Should Be Reported in a Peer-reviewed JournalRoy Fleischmann
Current Opinion in Rheumatology|February 24, 2012
Novel small-molecular therapeutics for rheumatoid arthritisRoy Fleischmann
Expert Opinion on Pharmacotherapy|August 23, 2017
A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexateRoy Fleischmann
Nature Reviews. Rheumatology|November 4, 2017
Therapy: Biosimilars in rheumatology - why, how and when in 2017Roy Fleischmann
The Journal of Rheumatology|July 17, 2019
Dr. Fleischmann repliesRoy Fleischmann
The Lancet. Rheumatology|January 26, 2024
Tofacitinib monotherapy in psoriatic arthritis-what is missing?Roy Fleischmann
Rheumatology and Therapy|October 18, 2016
Living with Psoriatic Arthritis: A Patient's and Physician's PerspectiveAlan Simmons, Roy Fleischmann
Molecular Interventions|March 3, 2004
Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritisRoy Fleischmann, Dave Shealy
Pageof 19

Showing results (21-30 of 190) with videos related to

Sort By:
Pageof 19
Nature Clinical Practice. Rheumatology|August 1, 2007
Primer: establishing a clinical trial unit--obtaining studies and patientsRoy Fleischmann
Expert Opinion on Biological Therapy|March 17, 2010
The clinical efficacy and safety of certolizumab pegol in rheumatoid arthritisRoy Fleischmann
The Journal of Rheumatology|April 16, 2021
The Results of Well-conducted Negative Clinical Trials Should Be Reported in a Peer-reviewed JournalRoy Fleischmann
Current Opinion in Rheumatology|February 24, 2012
Novel small-molecular therapeutics for rheumatoid arthritisRoy Fleischmann
Expert Opinion on Pharmacotherapy|August 23, 2017
A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexateRoy Fleischmann
Nature Reviews. Rheumatology|November 4, 2017
Therapy: Biosimilars in rheumatology - why, how and when in 2017Roy Fleischmann
The Journal of Rheumatology|July 17, 2019
Dr. Fleischmann repliesRoy Fleischmann
The Lancet. Rheumatology|January 26, 2024
Tofacitinib monotherapy in psoriatic arthritis-what is missing?Roy Fleischmann
Rheumatology and Therapy|October 18, 2016
Living with Psoriatic Arthritis: A Patient's and Physician's PerspectiveAlan Simmons, Roy Fleischmann
Molecular Interventions|March 3, 2004
Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritisRoy Fleischmann, Dave Shealy
Pageof 19